Tamoxifen in Malignant Melanoma

Richard A. Nesbit; Robert L. Woods; Martin H.N. Tattersall; Richard M. Fox; John F. Forbes; Ian R. Mackay; M. Goodyear

doi:10.1056/NEJM197911293012218

Tamoxifen in Malignant Melanoma

Richard A. Nesbit, Robert L. Woods, Martin H.N. Tattersall, Richard M. Fox, John F. Forbes, Ian R. Mackay, M. Goodyear

Research output: Contribution to journal › Letter › peer-review

46 Citations (Scopus)

Abstract

To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.¹ We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

Original language	English
Pages (from-to)	1241-1242
Number of pages	2
Journal	New England Journal of Medicine
Volume	301
Issue number	22
DOIs	https://doi.org/10.1056/NEJM197911293012218
Publication status	Published - Nov 29 1979
Externally published	Yes

ASJC Scopus Subject Areas

General Medicine

PubMed: MeSH publication types

Case Reports
Letter

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJM197911293012218

Cite this

@article{ba47060e5ce0418ea7b69cfde64d5e6e,

title = "Tamoxifen in Malignant Melanoma",

abstract = "To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.",

author = "Nesbit, {Richard A.} and Woods, {Robert L.} and Tattersall, {Martin H.N.} and Fox, {Richard M.} and Forbes, {John F.} and Mackay, {Ian R.} and M. Goodyear",

year = "1979",

month = nov,

day = "29",

doi = "10.1056/NEJM197911293012218",

language = "English",

volume = "301",

pages = "1241--1242",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "22",

}

TY - JOUR

T1 - Tamoxifen in Malignant Melanoma

AU - Nesbit, Richard A.

AU - Woods, Robert L.

AU - Tattersall, Martin H.N.

AU - Fox, Richard M.

AU - Forbes, John F.

AU - Mackay, Ian R.

AU - Goodyear, M.

PY - 1979/11/29

Y1 - 1979/11/29

N2 - To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

AB - To the Editor: In the issue of July 5, Lerner et al. reported a possible adverse effect of oral contraceptives on the course of malignant melanoma. However, estrogens have been used to treat patients with malignant melanoma.1 We have treated 26 patients with advanced malignant melanoma with the antiestrogen tamoxifen, 20 to 40 mg per day. There were five women (four postmenopausal and one premenopausal) and 21 men. Five patients had received previous immunotherapy (BCG vaccine) and three had received previous chemotherapy. The dominant site of disease was soft tissue in 15 patients, viscera in nine patients, and bone and.

UR - http://www.scopus.com/inward/record.url?scp=0018602550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018602550&partnerID=8YFLogxK

U2 - 10.1056/NEJM197911293012218

DO - 10.1056/NEJM197911293012218

M3 - Letter

C2 - 503125

AN - SCOPUS:0018602550

SN - 0028-4793

VL - 301

SP - 1241

EP - 1242

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 22

ER -

Tamoxifen in Malignant Melanoma

Abstract

ASJC Scopus Subject Areas

PubMed: MeSH publication types

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this